Trials / Completed
CompletedNCT04886232
A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Merz North America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to demonstrate non-inferiority of VP1 Lido US versus an approved hyaluronic acid dermal filler following deep (subdermal and/or supraperiosteal) injection of the cheek for volume augmentation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | VP1 Lido US | Hyaluronic acid dermal filler containing lidocaine |
| DEVICE | Restylane Lyft Lidocaine | Hyaluronic acid dermal filler containing lidocaine |
Timeline
- Start date
- 2021-05-25
- Primary completion
- 2022-03-25
- Completion
- 2023-05-16
- First posted
- 2021-05-14
- Last updated
- 2023-05-24
Locations
10 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04886232. Inclusion in this directory is not an endorsement.